Craig Crews is the founder of Arvinas. Arvinas has raised $171M in total funding. Latest round: Series D. Backed by Connecticut Innovations.
Craig M. Crews, PhD, is a co-founder of Arvinas, a clinical-stage biopharmaceutical company focused on developing PROTAC targeted protein degraders as therapeutics. He is also a professor at Yale School of Medicine, where his research focuses on targeted protein degradation. In August 2024, Crews founded Halda Therapeutics, which subsequently secured $126 million in Series B extension financing.
Full founder directory · Investor directory · Company funding database · Fundraising library